EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Long-term outcomes of antithrombotic treatment for retinal vein occlusion

Davide Sacchet, Corrado Lodigiani, Clara Sacco, Stefano Barco, Simon Wolf, Sandrine Zweifel, Marco Paolo Donadini, Luca Librè, Lorenza Bertù, Walter Ageno

Research and Practice in Thrombosis and Haemostasis · 2026-10 · 10 (7) · 106976

DOI: 10.1016/j.rpth.2026.106976 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Research and Practice in Thrombosis and Haemostasis, 2026-10. Verfasst von Davide Sacchet und 9 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Hemorrhagic Diseases Unit, Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Rozzano, Milan, Italy. Hauptthemen laut MEDLINE: Retinal Vein Occlusion, Fibrinolytic Agents, Anticoagulants, Platelet Aggregation Inhibitors. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Italian Government Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Retinal vein occlusion (RVO) is a leading cause of visual impairment. Several cardiovascular and thrombotic predisposing factors have been linked to RVO. Antithrombotic agents are commonly prescribed, but their effectiveness for visual recovery and long-term outcomes remains uncertain.

Objectives

To study the course of long-term clinical outcomes in RVO patients.

Methods

In this multicenter, retrospective, observational study of patients with an index RVO at 3 academic hospitals, we estimated the risk of recurrent RVO, cardiovascular events, venous thromboembolic events, bleeding complications, and death, reported as incidence rates per 100 person-years, and compared these rates between patients treated with antithrombotic drugs and those untreated.

Results

Between 2004 and 2023, 198 patients were enrolled (median age, 65 years; IQR, 54-75; 105 females, 53.0%) and followed for a median of 2.6 years (IQR, 0.9-4.5); of these, 39.4% received antiplatelet therapy, 16.6% received anticoagulant therapy, and 44.0% received no antithrombotic treatment. The median duration of anticoagulant therapy was 46 days (IQR, 30-158), while that of antiplatelet therapy was 296 days (IQR, 124-947). The incidence rate ratios (IRRs) for cardiovascular events and mortality were higher in the untreated group (IRR, 6.04; 95% CI, 1.17-38.9 for cardiovascular events; IRR, 3.89; 95% CI, 1.29-12.3 for mortality) than in patients receiving antithrombotic treatment. For RVO recurrence and hemorrhagic complications, we found no differences between treated and untreated patients (IRR, 1.02; 95% CI, 0.18-3.97 for recurrent RVO; IRR, 1.12; 95% CI, 0.4-2.76 for bleeding complications).

Conclusion

In this real-world cohort study of RVO, our data suggest that patients with RVO should undergo careful cardiovascular risk assessment. Antithrombotic therapy should not be used routinely after RVO, only when indicated by established cardiovascular prevention principles or specific clinical circumstances. Notably, rates of recurrent RVO and bleeding complications were similar between treated and untreated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal Vein OcclusionFibrinolytic AgentsAnticoagulantsPlatelet Aggregation InhibitorsHumansFemaleMaleRetrospective StudiesAgedMiddle AgedTreatment OutcomeRecurrenceHemorrhageIncidenceRisk FactorsTime Factors

Stichwörter der Autor:innen

anticoagulantsheart disease risk factorsrecurrenceretinal vein occlusionthrombophilia

Substanzen

Fibrinolytic AgentsAnticoagulantsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Thrombosis and Hemorrhagic Diseases Unit, Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Department of Angiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Clinical Medicine, University of Insubria, Varese, Italy.
  • Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Förderung

  • Italian Government Ministry of Health

Zitieren

APA

Sacchet, D., Lodigiani, C., Sacco, C., Barco, S., Wolf, S., Zweifel, S., Donadini, M. P., Librè, L., Bertù, L., & Ageno, W. (2026). Long-term outcomes of antithrombotic treatment for retinal vein occlusion. Research and Practice in Thrombosis and Haemostasis, 10(7), 106976. https://doi.org/10.1016/j.rpth.2026.106976

Vancouver

Sacchet D, Lodigiani C, Sacco C, Barco S, Wolf S, Zweifel S, et al. Long-term outcomes of antithrombotic treatment for retinal vein occlusion. Research and Practice in Thrombosis and Haemostasis. 2026;10(7):106976. doi:10.1016/j.rpth.2026.106976

BibTeX
@article{Sacchet2026,
  author = {Sacchet, Davide and Lodigiani, Corrado and Sacco, Clara and Barco, Stefano and Wolf, Simon and Zweifel, Sandrine and Donadini, Marco Paolo and Librè, Luca and Bertù, Lorenza and Ageno, Walter},
  title = {Long-term outcomes of antithrombotic treatment for retinal vein occlusion},
  journal = {Research and Practice in Thrombosis and Haemostasis},
  year = {2026},
  volume = {10},
  number = {7},
  pages = {106976},
  doi = {10.1016/j.rpth.2026.106976}
}
Kostenlos starten →